Q-omics provides the consensus-scored UNC93B7 profile across patient tissues and cancer cell-line models. UNC93B7 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UNC93B7 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, UNC93B7 RNA expression shows 10,602 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where UNC93B7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC93B7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC93B7 survival associations across molecular data types. UNC93B7 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC93B7 RNA expression–survival associations across cancer types. High UNC93B7 expression shows unfavorable associations in OV, READ, LGG, PCPG and THCA, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for UNC93B7 RNA expression.
This table summarizes UNC93B7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for UNC93B7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC93B7 shows lower tumor expression in THCA and PRAD and higher tumor expression in KIRC, STAD, KIRP and ESCA. The THCA box plot shows higher UNC93B7 RNA expression in normal versus tumor tissue (log2 FC = −1.192, t-test p < 0.001).
This table shows molecular features associated with UNC93B7 in patient tissues and cancer cell lines. In patient samples, UNC93B7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
